Answers are grounded in this paper and cite their sources.
With this Special Issue “Rare non-Hodgkin lymphomas in childhood and adolescence: From rare to recognized entities”, the European Journal of Cancer (EJC) Pediatric Oncology (PO) is addressing the important topic of pathology (biology)-driven therapy de-escalation in pediatric non-Hodgkin lymphoma (NHL). Over the past 30–40 years pediatric oncology has achieved what once seemed unattainable, namely, high cure rates across the major NHL entities via mainly subtype- and stage-adapted intensive polychemotherapy.
No takes yet. Share an insight, caveat, or question.
Andishe Attarbaschi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: